Allogene Therapeutics Inc.
Allogene Therapeutics is a clinical‑stage immuno‑oncology company developing a portfolio of allogeneic CAR‑T and targeted therapies (UCART19, ALLO‑501, ALLO‑715, DLL3, Claudin18.2, FLT3) with strategic partnerships with Pfizer, Servier, Cellectis and MD Anderson.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 226
- HQ: South San Francisco
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.